Antofagasta Shares Drop 5% as Miner Cuts 2026 Copper Production Forecast 
Aviva First-Half Operating Profit Jumps 24% as Direct Line Deal Boosts Growth 
Paramount Weighs CNN Sale as $110B Warner Bros. Discovery Deal Faces Antitrust Fight 
Alphabet Shifts AI Strategy Toward Commercial Growth, Goldman Sachs Says 
ANZ Home Loan Applications Drop 12% After Australia Property Tax Changes 
Stripe, Advent Reportedly Pursue $53 Billion PayPal Takeover 
Thyssenkrupp Raises 2026 Profit Outlook as Steel and Materials Units Strengthen 
SMIC Shares Rally as Q2 Profit Surges 262% on Strong Chip Demand 
Pandora Shares Rise as Q2 Results Beat Forecasts, 2026 Outlook Raised 
Micron Stock Upgraded to Buy as New Street Sees $2 Trillion Valuation Potential 
Bernstein Picks BYD and Xiaomi as Top China EV Stocks Despite Weaker Demand 
Goldman Sachs Eyes Investors for Nvidia’s $500 Billion AI Financing Plan 
Australia’s Corporate Leaders Face Parliament Over KPMG Client Data Scandal 
Cisco Forecasts Strong Fiscal 2027 Growth as AI Networking Demand Surges 
Maersk Raises 2026 Earnings Outlook as Shipping Profits Beat Expectations 
Google Pushes Gemini AI Overhaul as Sergey Brin Targets Model Supremacy 
Bill Ackman’s Pershing Square Returns to Netflix With Major New Stake 
 - EconoTimes)
Add as a preferred source on Google
NEW ORLEANS, March 03, 2017 -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., reminds investors that they have until March 13, 2017 to file lead plaintiff applications in a securities class action lawsuit against Novo Nordisk A/S (NYSE:NVO), if they purchased the Company’s American Depository Receipts (“ADRs”) between the expanded period of February 5, 2015 and October 27, 2016, inclusive (the “Class Period”). The action is pending in the United States District Court for the District of New Jersey.
What You May Do
If you purchased ADRs of Novo Nordisk and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn ([email protected]). If you wish to serve as a lead plaintiff in this class action, you must petition the Court by March 13, 2017.
About the Lawsuit
Novo Nordisk and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On August 5, 2016, the Company announced disappointing earnings for the 2016 second quarter. Then, on October 28, 2016, the Company disclosed that it was cutting its long-term profit growth by 50% and that it had received a Civil Investigative Demand from the U.S. Attorney’s Office for the Southern District of New York seeking information relating to contracts and business relationships concerning its insulin products.
On this news, the price of Novo Nordisk’s ADRs plummeted.
About Kahn Swick & Foti, LLC
KSF, whose partners include the Former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana.
To learn more about KSF, you may visit www.ksfcounsel.com.
Contact: Kahn Swick & Foti, LLC Lewis Kahn, Managing Partner [email protected] 1-877-515-1850 206 Covington St. Madisonville, LA 70447
